Skip to main content

Advertisement

Figure 8 | Thrombosis Journal

Figure 8

From: Global assays and the management of oral anticoagulation

Figure 8

Summary of in vitro NOAC reversal data with PCC, activated PCC and rFVIIa. Data on in vitro NOAC reversal in human whole blood or plasma with APTT, PT, TEG/TEM (TF-triggered) and TGA (TF-triggered) were from the following studies: 1Marlu et al. [101], ex vivo reversal with plasma from NOAC treated healthy volunteers. 2Perzborn et al. [100], in vitro spiking experiments. 3Herrmann et al. [102], ex vivo reversal with plasma and whole blood from NOAC treated patients. 4Khoo et al. [103], ex vivo reversal with plasma from NOAC treated patients. 5Dinkelaar et al. [32,68], in vitro spiking experiments. 6Escolar et al. [35], in vitro spiking experiments. 7Additional in vitro data presented in this review. Ex vivo reversal studies with NOAC-treated patients are difficult to interpret due to lack of a reliable reference point, i.e. plasma from the same patient not treated with NOAC. Ex vivo reversal in patients, if present, is therefore classified as partial. In the overall classification (colored marks), in vitro spiking studies and ex vivo reversal studies with healthy volunteers are dominators. Most readout parameters only show partial reversal of anticoagulation.

Back to article page